NKMax Co Ltd
KOSDAQ:182400
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
NKMax Co Ltd
Research & Development
NKMax Co Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
N
|
NKMax Co Ltd
KOSDAQ:182400
|
Research & Development
-₩2.2B
|
CAGR 3-Years
39%
|
CAGR 5-Years
25%
|
CAGR 10-Years
2%
|
|
|
Celltrion Inc
KRX:068270
|
Research & Development
-₩208B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-14%
|
|
|
O
|
OliX Pharmaceuticals Inc
KOSDAQ:226950
|
Research & Development
-₩25.6B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
N/A
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Research & Development
-₩17.9B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Research & Development
-₩28.4B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-35%
|
CAGR 10-Years
-31%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Research & Development
-₩95.6B
|
CAGR 3-Years
-35%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
N/A
|
|
NKMax Co Ltd
Glance View
NKMAX Co., Ltd. engages in the development, manufacture, and sale of recombinant proteins and monoclonal antibodies. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2015-10-23. The firm is involved in the production and sale of recombinant proteins, monoclonal antibodies, NK cell activity test kits, cell therapy products, and in the provision of other related services. The NK cell activity test kits are provided under the name of NK Vue. The firm distributes its products within domestic market and to overseas markets.
See Also
What is NKMax Co Ltd's Research & Development?
Research & Development
-2.2B
KRW
Based on the financial report for Sep 30, 2025, NKMax Co Ltd's Research & Development amounts to -2.2B KRW.
What is NKMax Co Ltd's Research & Development growth rate?
Research & Development CAGR 10Y
2%
Over the last year, the Research & Development growth was 61%. The average annual Research & Development growth rates for NKMax Co Ltd have been 39% over the past three years , 25% over the past five years , and 2% over the past ten years .
